CONTACT

Charles DUMONTET
Team leader

charles.dumontet@chu-lyon.fr


+33 (0)4 78 77 71 23

Faculté Rockefeller
4th floor, stairs B
8 avenue Rockefeller
69008 Lyon
France

DUMONTET Charles
Professeur des Universités - Praticien hospitalier (UCBL - HCL)
charles.dumontet@chu-lyon.fr

SEVE Pascal
Professeur des Universités - praticien hospitalier (UCBL - HCL)
pascal.seve@chu-lyon.fr
GAGNIEU Marie-Claude
Praticien hospitalier HCL
marie-claude.gagnieu@chu-lyon.fr
THOMAS Xavier
Praticien hospitalier HCL
xavier.thomas@chu-lyon.fr
BOUSFIHA Zineb
Adjointe technique
zineb.bousfiha@univ-lyon1.fr
TREDAN Olivier
Praticien hospitalier CLB
olivier.tredan@lyon.unicancer.fr
CLERET Aurore
Assistant ingénieur
aurore.cleret@univ-lyon1.fr
CROS-PERRIAL Emeline
Assistant ingénieur
emeline.cros@univ-lyon1.fr
MATERA Eva-Laure
Assistant ingénieur
eva-laure.peiller@univ-lyon1.fr
EVESQUE Anne
Assistant ingénieur
anne.evesque@univ-lyon1.fr
CHETTAB Kamel
MATHE Doriane
Assistant ingénieur
doriane.poloni@univ-lyon1.fr
JORDHEIM Lars Petter
Maître de conférences des Universités (UCBL)
lars-petter.jordheim@univ-lyon1.fr
GENESTE Aline
SAUVEUR Juliette
SPASEVSKA Ivana
CADASSOU Octavia
CASSAGNES Laure-Estelle

Attaché Temporaire d'Enseignement et de Recherche

laure-estelle.cassagnes@univ-lyon1.fr
RAZA Muhammad-Zawwad
GRASSELY Chloé
Voir les objectifs et projets Voir les publications
Founding

ANR Blanc 
INCa Projets libres 
ARC Foundation
Ligue Nationale Contre le Cancer 
CLARA – Preuve de Concept

 

OBJECTIVES

In our group, we study the mechanisms of action of monoclonal antibodies that are targeting cancer cells. We also study the mechanism of resistance towards these biomolecules in order to increase the activity of therapies based on monoclonal antibodies in patients with hematological malignancies or solid tumors.

PROJECT

 

The Anticancer Antibodies team, composed by medical doctors, post-docs, students and technicians, possess and expertise in the field of preclinical in vitro and in vivo modeling, as well as in the identification and the validation of predictive or prognostic factors in clinical samples and the development of new compounds or new therapeutic strategies. Our work is focused on monoclonal antibodies used in the treatment of hematological malignancies or breast cancer.

We explore the nature and the role of effector cells implicated in the antitumoral activity of these monoclonal antibodies, in addition to the role of the cells of the micro-environment such as adipocytes. We also search for new apoptotic signaling pathways induced by antibodies in the cancer cells, we develop new strategies for sensitization of cancer cells to monoclonal antibodies, and we evaluate the clinical relevance of observations made in preclinical models.

 

The Anticancer Antibodies team, composed by medical doctors, post-docs, students and technicians, possess and expertise in the field of preclinical in vitro and in vivo modeling, as well as in the identification and the validation of predictive or prognostic factors in clinical samples and the development of new compounds or new therapeutic strategies. Our work is focused on monoclonal antibodies used in the treatment of hematological malignancies or breast cancer.

We explore the nature and the role of effector cells implicated in the antitumoral activity of these monoclonal antibodies, in addition to the role of the cells of the micro-environment such as adipocytes. We also search for new apoptotic signaling pathways induced by antibodies in the cancer cells, we develop new strategies for sensitization of cancer cells to monoclonal antibodies, and we evaluate the clinical relevance of observations made in preclinical models.

PUBLICATIONS

2015
Duong MN, Cleret A, Matera EL, Chettab K, Mathe D, Valsesia-Wittmann S, Clemenceau B, Dumontet C. Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. Breast Cancer Res, 2015; 17(1): 57.

Cividini F, Pesi R, Chaloin L, Allegrini S, Camici M, Cros-Perrial E, Dumontet C, Jordheim LP, Tozzi MG. The purine analog fludarabine acts as a cytosolic 5'-nucleotidase II inhibitor. Biochem Pharmacol, 2015; 94(2): 63-68.

Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudzinski M, Fejerman L, Greenberg A, Huntsman S, Jamroziak K, Jurczyszyn A, Kumar S, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Vangsted AJ, Watek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nat Commun, 2015; 6 :7539.

Chettab K, Roux S, Mathe D, Cros-Perrial E, Lafond M, Lafon C, Dumontet C, Mestas JL. Spatial and Temporal Control of Cavitation Allows High In Vitro Transfection Efficiency in the Absence of Transfection Reagents or Contrast Agents. PLoS One, 2015; 10(8): e0134247.

Thomas X. Blinatumomab: a new era of treatment for adult ALL? Lancet Oncol, 2015; 16(1): 6-7.

Tredan O, Menetrier-Caux C, Ray-Coquard I, Garin G, Cropet C, Verronese E, Bachelot T, Rebattu P, Heudel PE, Cassier P, Chabaud S, Croughs T, Dupont P, Cadore AC, Clapisson G, Delgado A, Bardin-dit-Courageot C, Rigal C, N'Kodia A, Gilles-Afchain L, Morre M, Perol D, Blay JY, Caux C. ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. Ann Oncol, 2015; 26(7): 1353-1362.

2014
Thomas XG, Arthur C, Delaunay J, Jones M, Berrak E, Kantarjian HM. A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. Clin Lymphoma Myeloma Leuk, 2014; 14(1): 68-72.

Jordheim LP, Cros-Perrial E, Matera EL, Bouledrak K, Dumontet C. Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability. Clin Exp Pharmacol Physiol, 2014; 41(10): 817-824.

Reslan L, Dalle S, Herveau S, Perrial E, Dumontet C. Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. Leuk Lymphoma, 2014; 55(1): 188-190.  

2013

Jordheim LP, Durantel D, Zoulim F, Dumontet C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov, 2013; 12(6): 447-464.

Tagoug I, Jordheim LP, Herveau S, Matera EL, Huber AL, Chettab K, Manie S, Dumontet C. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors. Clin Cancer Res, 2013; 19(13): 3556-3566.

2012

Marechal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, Andre T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Deviere J, Emile JF & Van Laethem JL. Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma. Gastroenterology, 2012, 143, (3): 664-674.

Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, Poncelet P, San Miguel JF, Legrand O, Deangelo DJ, Giles FJ & Marie JP. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs, 2012, 30, (3): 1121-1131.

Reiman T, Lai R, Veillard AS, Paris E, Soria JC, Rosell R, Taron M, Graziano S, Kratzke R, Seymour L, Shepherd FA, Pignon JP & Seve P. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol, 2012, 23, (1): 86-93.

 

2011

Dalle S, Poulalhon N & Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011a, 365, (15): 1448-1449; author reply 1450.

Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A, Friess T, Umana P, Klein C & Dumontet C. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther, 2011, 10 (1): 178-185.

Jordheim LP, Seve P, Tredan O & Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol, 2011, 12 (7): 693-702.

 


Cliquez ici pour voir une liste complète des publications des membres de l'équipe Anticorps-Anticancer du 1er janvier 2011 au 11 janvier 2016.
CENTRE DE RECHERCHE EN CANCEROLOGIE DE LYON (CRCL)
UMR INSERM 1052 CNRS 5286 - CENTRE LEON BERARD
Copyright 2011. CRCL
SUIVEZ LES ACTUALITES
DU CRCL SUR TWITTER :